Replimune Group Inc
NASDAQ:REPL
| Market Cap (Intraday) | 845.67M |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $10.03 |
| 50-Day MA | $9.15 |
| 200-Day MA | $11.03 |
Replimune Group Inc Stock, NASDAQ:REPL
500 Unicorn Park Drive, Suite 303, Woburn, Massachusetts 01801
United States of America
Phone: +1.781.222.9600
Number of Employees: 331
Description
Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip Astley-Sparke, Colin A. Love, and Robert Coffin in March 2015 and is headquartered in Woburn, MA.